To assess risk factors for development of candidal blood stream infections (CBSIs), a prospective cohort study was performed at 6 sites that involved all patients admitted to the surgical intensive care unit (SICU) for 148 h over a 2-year period. Among 4276 such patients, 42 CBSIs occurred (9.82 CBSIs per 1000 admissions). The overall incidence was 0.98 CBSIs per 1000 patient days and 1.42 per 1000 SICU days with a central venous catheter in place. In multivariate analysis, factors independently associated with increased risk of CBSI included prior surgery (relative risk [RR], 7.3), acute renal failure (RR, 4.2), receipt of parenteral nutrition (RR, 3.6), and, for patients who had undergone surgery, presence of a triple lumen catheter (RR, 5.4). Receipt of an antifungal agent was associated with decreased risk (RR, 0.3). Prospective clinical studies are needed to identify which antifungal agents are most protective and which high-risk patients will benefit from antifungal prophylaxis.
(ICUs) [1] [2] [3] [4] [5] . Previous studies have suggested that possible risk factors for candidal BSI (CBSI) may include receipt of antibiotic agents, chemotherapy, or steroids; the presence of intravascular catheters; receipt of parenteral nutrition; surgery; hospitalization in an ICU; malignancy; neutropenia; and prior fungal colonization [2, 3, [6] [7] [8] [9] [10] [11] [12] [13] [14] . These data are limited by the fact that the large majority of studies have been retrospective, with data gathered from a single institution over a long period of time (e.g., a decade or more) [14] .
Among patients cared for in ICUs, those in surgical ICUs (SICUs) are thought to be at the greatest risk for developing a CBSI [15, 16] . Given reports of the 40%-60% mortality rate associated with CBSIs, the use of antifungal prophylaxis for surgical patients has emerged as a common practice. However, there are no data to indicate whether such use is beneficial in the ICU setting [17, 18] .
The National Epidemiology of Mycosis Survey (or NEMIS) was a prospective, multicenter study conducted at 6 geographically dispersed academic medical centers to examine rates of and risk factors for the development of CBSIs among patients in surgical and neonatal ICUs. A recent report from the NEMIS study group has described the methods employed in the surveillance and the great variation in the rate of CBSIs among patients in surgical and neonatal ICUs at various institutions [19] . Herein we describe the risk factors for the development of CBSIs among patients being cared for in SICUs, and we report results of molecular typing and susceptibility tests performed on Candida species isolates recovered from blood cultures.
PATIENTS AND METHODS
Study design. The NEMIS was a prospective multicenter cohort study conducted in SICUs at 6 sites in the United States [19] : Atlanta (Grady Memorial Hospital/Emory University School of Medicine); Iowa City, Iowa (University of Iowa); Los Angeles (Harbor-UCLA Medical Center); New York City (Columbia-Presbyterian Medical Center); Portland (Oregon Health Sciences University); and San Antonio (University of Texas-San Antonio Health Sciences Center and the Veterans Affairs Medical Center). The study period was from October 1993 to November 1995, but the study was initiated and data were collected slightly later at some centers than at others. All centers enrolled patients for a minimum of 18 months.
Study population and case definition. All patients admitted to an SICU at these centers for 148 h were enrolled in the study. Case patients were defined as those individuals who had a Candida species recovered from culture of a blood specimen collected 148 h after admission to the SICU. For case patients, risk factor analysis included data collected up to the time of the development of the CBSI, whereas for non-case patients in the cohort, risk factor analyses included data collected for the entire duration of the stay in the SICU.
Data abstraction. Clinical and epidemiological data on all patients enrolled in the study were collected daily by dedicated study nurses, as previously described [19] . In the first year of the study, all azole drug use was recorded as a single variable, whereas in the second year information was recorded about the specific azole drugs administered (e.g., fluconazole, itraconazole, ketoconazole, miconazole, or clotrimazole). Severityof-illness measures, including American Society of Anesthesia (ASA) scores [20] , Acute Physiology and Chronic Health Evaluation (APACHE) II scores [21] , and McCabe-Jackson scores [22] , were calculated for all patients at the time of admission to the SICU.
Microbiological testing. Rectal swabs and urine specimens for fungal surveillance culture were collected from each patient at the time of admission to the SICU and each week thereafter if the patient remained hospitalized in the SICU. Fungal surveillance cultures were incubated according to standard laboratory methods and isolates were identified with use of the commercial identification system API20C and VITEK Yeast Identification (bioMérieux VITEK) [23] . Antifungal susceptibility of Candida species isolates was determined by testing them against amphotericin B, flucytosine, fluconazole, and itraconazole with use of a standard broth-microdilution method, as described elsewhere [24] . Molecular typing of Candida species isolates was performed by means of pulsed-field gel electrophoresis with use of the restriction enzyme BssHII or SfiI [23] ; Candida albicans isolates were typed with use of the species-specific probe Ca3 [25] . Thirty-five of 42 Candida species isolates recovered from blood were available for typing. Banding patterns were analyzed for relatedness with use of a computerassisted system (Dendron software, version 2.0; Solltech).
Statistical analysis. Infection rates (the number of CBSIs per 1000 patient-days) were compared between groups of persons in different categories of the variable examined; the rate ratio was used as a measure of relative risk [26] . Univariate and multivariate analyses were performed with SAS software (SAS). A P value of р.05 was considered significant.
A stepwise approach was used to determine which of the studied factors or variables were most strongly associated with CBSI. Variables with significant colinearity were dropped from the analysis. The remaining variables were evaluated for associations with the development of CBSI with use of proportional hazards and logistic regression [27, 28] . Because both methods yielded similar results, only the results from the analysis per- formed with proportional hazards regression are presented. In order to evaluate whether risk factors for the development of CBSI were different for SICU patients who did and did not have surgery, 2 regression models were used (one that included all patients in the study and another that included only those who had undergone surgery). During regression modeling, all variables that did not significantly contribute to the model were removed from consideration with use of a backward stepwise method. Regardless of statistical significance, the hospital variable was left in both models to account for potential unmeasured differences between different institutions in the risk of developing CBSI.
RESULTS
During the study period, 42 CBSIs developed among the 4276 admitted patients enrolled at the 6 different academic medical centers (9.82 CBSIs per 1000 admissions). Candida species accounted for 9.2% of the total number of BSIs ( ). The n p 458 overall rate of CBSIs was 0.98 per 1000 SICU patient-days, or [19] . In univariate analysis, the CBSI rates at Grady Memorial Hospital and ColumbiaPresbyterian Hospital were significantly higher than that at Oregon (table 1) , but in multivariate analyses, residence at a particular institution was not associated with an increased risk of CBSI infection (see the section on Multivariate Analysis, below). A higher severity-of-illness value, as indicated by the McCabe-Jackson, APACHE II, or ASA score at the time of admission to the SICU, was not associated with increased risk of developing a CBSI in univariate analysis ( ). Seventy-five P p .04 percent of SICU patients underwent surgery; this group had a significantly higher rate of CBSI than did the group who did not require surgery (table 2) . There was a trend toward increased risk of infection among those who had an abdominal procedure performed (RR, 1.8; 95% CI, 0.9-3.4; ); those P p .06 who had a neurosurgical procedure performed were at significantly lower risk (RR, 0.2; 95% CI, 0.1-0.7; ), and no P p .02 increased or decreased risk was seen among patients who underwent orthopedic, cardiovascular, ear/nose/throat, gynecologic, or transplantation surgery (table 2) .
Medications associated with an increased risk of developing a CBSI in univariate analysis included receipt of parenteral nutrition, intralipid agents, vancomycin, or an antibiotic agent with activity against anaerobic organisms (including combinations of imipenem, metronidazole, clindamycin, and the extended-spectrum penicillins/b-lactamase-inhibitor drugs, such as ticarcillin/clavulanate, piperacillin/tazobactam, and ampicillin/sulbactam; table 3). Treatment with antifungal agents (amphotericin B, azoles, nystatin, or any antifungal drug) were not significantly associated with risk for developing CBSI in univariate analysis (table 4) ; however, in univariate analysis there was a trend toward an association between receipt of antifungal agents and a decreased risk of developing CBSI (RR, 0.6; 95% CI, 0.3-1.1;
; table 4). P p .09 No increased risk of developing infection was associated with the individual use of the following antibiotic agents: aminoglycosides, penicillins (including extended-spectrum penicillins and b-lactam/b-lactamase inhibitor drugs), first-, second-, or third-generation cephalosporins, imipenem, fluoroquinolones, clindamycin, metronidazole, and erythromycin (data not shown). There were no CBSIs among the 784 SICU patients who did not receive an antibiotic agent. For the 3512 patients who did receive у1 antibiotic agents, there was no significant difference in rates of CBSIs with stratification by the number of days antibiotic agents were received (data not shown). Receipt of antacids, H 2 blockers, corticosteroids, or sucralfate also was not associated with risk of developing CBSI (data not shown).
Among patients who developed acute renal failure, shock, or disseminated intravascular coagulation, the rate of CBSI was significantly higher than it was among patients who did not develop these conditions (table 5). Among patients who had acute respiratory distress syndrome or developed a bacterial BSI, the rate of subsequent CBSI was higher than among patients who did not develop these conditions, but the differences were not statistically significant (table 5) .
Risk after colonization. As part of the study protocol, rectal swabs and urine specimens for Candida surveillance cultures were collected on admission to the SICU and then weekly for patients who remained hospitalized in the SICU. Thirty percent of patients ( ) had Candida species recovered n p 1280 in rectal surveillance cultures, and 15% of patients ( ) n p 627 had a positive urine culture for Candida species (table 6). The positive predictive value for developing CBSI after a rectal culture was positive for Candida was only 2.0% (26/1280), and for a positive urine culture it was 2.7% (17/627). Among patients who had Candida species recovered from urine, the rate ), in addition to the factors noted above. Hav-P p .03 ing undergone neurosurgical or ear/nose/throat surgery was associated with decreased risk of subsequent CBSI (table 7) . Receipt of an antifungal medication was significantly associated with decreased risk, as it was in the previous model. Susceptibility testing and molecular typing. Antifungal susceptibility testing was performed on Candida isolates recovered from 35 of the 42 patients who developed a BSI (table 8). All isolates were susceptible to amphotericin B, 34 (97%) to flucytosine, and 31 (89%) were susceptible to fluconazole and itraconazole. Two of 8 C. glabrata isolates were resistant to fluconazole (MIC, у64 mg/mL), and 1 additional isolate demonstrated dose-dependent susceptibility (MICs, 18 mg/mL and !64 mg/mL). Two of 26 other Candida isolates (1 C. albicans [24] for susceptibility testing are as follows. Amphotericin B: no break point established. Flucytosine: susceptible, р4 mg/mL; intermediate, 8-16 mg/ mL; resistant, у32 mg/mL. Fluconazole: susceptible, р8 mg/mL; susceptible-dose dependent, 16-32 mg/mL; resistant, у64 mg/mL. Itraconazole: susceptible, р0.12 mg/mL; susceptible-dose dependent, 0.25-0.5 mg/mL; resistant, у1 mg/mL. and 1 C. tropicalis) were resistant to fluconazole (table 8). Molecular typing studies with use of pulsed-field gel electrophoresis, electrophoretic karyotyping, and (for C. albicans) a Ca3 probe were carried out on paired isolates from cultures of urine and blood samples from 18 patients whose urine cultures were positive for a Candida species before the onset of CBSI. Seventeen of 18 paired isolates had identical banding patterns.
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DISCUSSION
The NEMIS SICU study is the largest prospective multicenter study to evaluate risk factors for the development of CBSI among SICU patients. There was a 6-fold variation in infection rates between institutions, from a low of 0.28 per 1000 patientdays to a high of 1.75 per 1000 patient-days. The 2 institutions with the highest rates of CBSIs are urban hospitals that care for large numbers of trauma patients. Previously reported data from the National Nosocomial Infections Surveillance (NNIS) system suggest that such patients have the greatest risk of developing nosocomial fungal infections [2, 3] . The fact that being a patient in the SICU at either of these institutions (in New York and Atlanta) was not independently associated with increased risk for development of CBSI in the multivariate analysis suggests that other risk factors accounted for the higher rate of CBSIs at those institutions.
It is interesting that ∼25% of all patients admitted to an SICU did not undergo a surgical procedure. The risk of this subset of SICU patients developing a CBSI was clearly different than that of patients who underwent a surgical procedure. Patients who underwent a surgical procedure or had a CVC were ∼11 times more likely to develop candidemia. Forty-one of the 42 CBSIs occurred in patients who had surgery and among those who had a CVC, with a rate of 1.2 per 1000 patient-days, versus 0.11 per 1000 patient-days for those who did not have a surgical procedure or a CVC.
In multivariate analyses, risk factors that were independently associated with increased risk of CBSI in our study included prior surgery (RR, 7.3), acute renal failure (RR, 4.2), and receipt of parenteral nutrition (RR, 3.6). Receipt of an antifungal drug significantly reduced the risk of developing a CBSI (RR, 0.3). When the model included only patients who underwent surgery, results were similar, but having had a triple-lumen catheter also proved to be a risk factor for developing CBSI (RR, 5.4). Our study helps further define the independent risk factors for CBSI in SICU patients and should help better identify highrisk patients in the SICU setting.
Potential risk factors for developing candidemia identified in previous studies have included receipt of antimicrobial agents, corticosteroids, chemotherapy, or parenteral therapy; hematological or solid organ malignancy; neutropenia; extensive surgery or burns; mechanical ventilation; a stay in an ICU (especially a surgical or neonatal ICU); an indwelling CVC or hemodialysis; and prior fungal colonization [2, 3, 6-11, 29, 30] . These studies have most frequently involved either patients with hematologic or solid organ malignancies exclusively or mixed patient populations [3] . Many of these previous studies have been limited by the fact that they often obtained data from a single institution or over a long period of time in order to ensure an adequate number of cases for review. In addition, few studies were prospective in design, and the few prospective studies have not focused on SICU populations. The large quantity of data and extent of data collection may account for the differences between our study and previous studies.
In our study, a high mortality rate (41%) was noted among patients who developed CBSIs, comparable to data from previous reports [3, [31] [32] [33] [34] [35] . Because of the high mortality rate among patients who develop CBSIs, it has been suggested that prophylactic, presumptive, or empirical therapy be given to high-risk patients in the SICU [16, 17, 36, 37] . These strategies are frequently employed, and a number of institutions have developed algorithms for deciding whether to use antifungal therapy for at-risk patients who do not have a proven invasive candidal infection [16, [38] [39] [40] . Previous investigators reported the use of oral nystatin or ketoconazole [37] , but recent recommendations have focused on the use of fluconazole [16] . However, how to identify high-risk patients has been incompletely defined and has varied in different reports; there are few data on the efficacy of antifungal prophylaxis or preemptive interventions for SICU patients.
The British Society for Antimicrobial Chemotherapy Working Party has recommended empirical therapy for high-risk patients who have a urine culture that is positive for Candida and who have a "deteriorating clinical status" [38] , whereas other investigators have recommended presumptive therapy for any ICU patient who has fungal colonization [36] . Our finding that fungal colonization (of the urinary tract alone and/or rectum) does not have a high positive predictive value raises doubts about this approach.
Prophylactic use of fluconazole has been shown to reduce the incidence of invasive and superficial fungal infections among bone marrow transplantation patients in randomized controlled trials [39] , but the emergence of infections due to natively resistant Candida species, such as Candida krusei, has been noted with fluconazole prophylaxis in this patient population [40] . Results of fluconazole prophylaxis among patients who have neutropenia and acute leukemia have been conflicting; one study showed no statistically significant reduction in invasive fungal infections [41] , whereas a more recent study did show a significant reduction in invasive fungal infections [42] . Eggimann et al. [43] conducted a randomized, placebocontrolled trial to study the efficacy of fluconazole prophylaxis among 49 high-risk surgical patients with recurrent gastrointestinal perforations or anastomotic leakages. They reported that patients who received fluconazole were less likely to have abdominal colonization or infection (peritonitis) with Candida species, but they were unable to assess whether the prophylaxis affected the risk of acquiring a CBSI because of the small number of patients enrolled.
The finding in our study that receipt of an antifungal agent was associated with a reduced risk of developing CBSI for SICU patients is important and has not been reported from previous epidemiological investigations. In our study, the use of antifungal agents was determined by the physicians caring for the patients, and guidelines for antifungal use were neither provided nor part of the study protocol. A limitation of our study was that data on the specific type of azole drug used (e.g., fluconazole, ketoconazole, itraconazole, clotrimazole, or miconazole) were not recorded in the first year of the study. This limited our ability to further determine which antifungal drug (e.g., amphotericin B or a specific azole agent) was protective. Prospective clinical trials are needed to determine which highrisk patients would benefit from prophylaxis and which antifungal agents would be most useful.
Several authors have recommended performance of serial fungal surveillance cultures and initiation of presumptive antifungal therapy if any degree of fungal colonization is noted [17, 36] , if patients are colonized at у2 sites, or if the colonization index is high [44] or candiduria is present in highrisk patients who are clinically unstable [38] . In our study, specimens of urine and rectal swabs for fungal surveillance culture were obtained on admission to the SICU and weekly thereafter. In 17 of 18 cases, molecular typing indicated that the colonizing strain was identical to the Candida isolate subsequently recovered from blood. Fungal colonization (defined as a urine or rectal swab culture positive for Candida species) was not associated with a statistically significant increase in risk of CBSI in univariate or multivariate analyses. Overall, 30% of the 4276 patients in the study had rectal colonization with a Candida species, 15% had urinary colonization, and 11% had both rectal and urinary colonization; however, only ∼1% of the patients in the study developed a CBSI. The finding of urinary or rectal fungal colonization alone, as assessed in our study, does not appear to be clinically useful for deciding when to start presumptive antifungal therapy.
Other investigators [17] have suggested that an elevated APACHE II score can help identify high-risk ICU patients who should start receiving prophylactic or presumptive antifungal therapy, given the findings of a retrospective study reported by Fraser et al. [33] that an elevated APACHE II score was associated with increased risk of developing CBSI. In our prospective study, however, a higher APACHE II or McCabe and Jackson score on admission was not associated with a significantly higher risk of developing CBSI.
In summary, this report demonstrates that the wide variation in the rate of CBSI between institutions is likely due to the underlying risk factors of the different patient populations served by the geographically dispersed institutions, and it defines a number of risk factors that are independently associated with increased risk of CBSI. The finding that receipt of an antifungal drug is associated with a reduced risk of developing CBSI indicates the need for additional investigations to further define which high-risk patients should be given prophylactic or presumptive therapy and which antifungal agents are most beneficial.
